Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1947 1
1950 1
1951 3
1952 1
1959 1
1965 1
1972 1
1987 1
1988 2
1993 3
1995 1
1997 2
1998 3
1999 3
2000 1
2002 2
2003 2
2004 5
2005 4
2006 3
2007 11
2008 5
2009 3
2010 1
2011 2
2012 4
2013 5
2015 3
2016 4
2017 3
2018 1
2019 1
2020 3
2021 4
Text availability
Article attribute
Article type
Publication date

Search Results

83 results
Results by year
Filters applied: . Clear all
Page 1
Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study.
Provenzano R, Besarab A, Wright S, Dua S, Zeig S, Nguyen P, Poole L, Saikali KG, Saha G, Hemmerich S, Szczech L, Yu KH, Neff TB. Provenzano R, et al. Am J Kidney Dis. 2016 Jun;67(6):912-24. doi: 10.1053/j.ajkd.2015.12.020. Epub 2016 Feb 2. Am J Kidney Dis. 2016. PMID: 26846333 Free article. Clinical Trial.
Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD.
Provenzano R, Besarab A, Sun CH, Diamond SA, Durham JH, Cangiano JL, Aiello JR, Novak JE, Lee T, Leong R, Roberts BK, Saikali KG, Hemmerich S, Szczech LA, Yu KH, Neff TB. Provenzano R, et al. Clin J Am Soc Nephrol. 2016 Jun 6;11(6):982-91. doi: 10.2215/CJN.06890615. Epub 2016 Apr 19. Clin J Am Soc Nephrol. 2016. PMID: 27094610 Free PMC article. Clinical Trial.
Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients.
Besarab A, Provenzano R, Hertel J, Zabaneh R, Klaus SJ, Lee T, Leong R, Hemmerich S, Yu KH, Neff TB. Besarab A, et al. Among authors: provenzano r. Nephrol Dial Transplant. 2015 Oct;30(10):1665-73. doi: 10.1093/ndt/gfv302. Epub 2015 Aug 3. Nephrol Dial Transplant. 2015. PMID: 26238121 Free PMC article. Clinical Trial.
Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for Treatment of Anemia in Chronic Kidney Disease: A Placebo-Controlled Study of Pharmacokinetic and Pharmacodynamic Profiles in Hemodialysis Patients.
Provenzano R, Tumlin J, Zabaneh R, Chou J, Hemmerich S, Neff TB, Yu KP. Provenzano R, et al. J Clin Pharmacol. 2020 Nov;60(11):1432-1440. doi: 10.1002/jcph.1648. Epub 2020 Jun 30. J Clin Pharmacol. 2020. PMID: 32603526 Free PMC article.
Hemostasis factors and aging.
Mari D, Coppola R, Provenzano R. Mari D, et al. Among authors: provenzano r. Exp Gerontol. 2008 Feb;43(2):66-73. doi: 10.1016/j.exger.2007.06.014. Epub 2007 Jul 4. Exp Gerontol. 2008. PMID: 17869046 Review.
PEGylated mucus-penetrating nanocrystals for lung delivery of a new FtsZ inhibitor against Burkholderia cenocepacia infection.
Costabile G, Provenzano R, Azzalin A, Scoffone VC, Chiarelli LR, Rondelli V, Grillo I, Zinn T, Lepioshkin A, Savina S, Miro A, Quaglia F, Makarov V, Coenye T, Brocca P, Riccardi G, Buroni S, Ungaro F. Costabile G, et al. Among authors: provenzano r. Nanomedicine. 2020 Jan;23:102113. doi: 10.1016/j.nano.2019.102113. Epub 2019 Oct 25. Nanomedicine. 2020. PMID: 31669084 Free article.
Introduction: Role of the medical director series.
Provenzano R, Hymes JL. Provenzano R, et al. Clin J Am Soc Nephrol. 2015 Feb 6;10(2):325. doi: 10.2215/CJN.11811214. Epub 2015 Jan 12. Clin J Am Soc Nephrol. 2015. PMID: 25583293 Free PMC article. No abstract available.
CKD: common, harmful, and treatable--World Kidney Day 2007.
Levey AS, Andreoli SP, DuBose T, Provenzano R, Collins AJ. Levey AS, et al. Among authors: provenzano r. Am J Kidney Dis. 2007 Feb;49(2):175-9. doi: 10.1053/j.ajkd.2006.12.013. Am J Kidney Dis. 2007. PMID: 17261418 Review. No abstract available.
83 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page